Proxi Biotech develops a bacteria-resistant vaccine to treat multi-drug-resistant bacterial infections.
Proxi Biotech has raised $526K in total funding. The most recent round was Convertible Note. The last funding was announced in February 2025.
Proxi Biotech's investors include BioInnovation Institute, BioInnovation Institute Venture Lab.
Proxi Biotech is headquartered in Copenhagen, Denmark.
Proxi Biotech develops a bacteria-resistant vaccine to treat multi-drug-resistant bacterial infections.
Proxi Biotech is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Proxi Biotech — Funding & Investors." VCBacked, February 25, 2025, https://www.vcbacked.co/company/proxi-biotech. Accessed September 30, 2026.
VCBacked. (2025). Proxi Biotech — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/proxi-biotech
{{cite web |title=Proxi Biotech — Funding & Investors |url=https://www.vcbacked.co/company/proxi-biotech |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated